vTv Therapeutics Inc.

## Signal Note: Baker Bros. Initiates Position in vTv Therapeutics (VTVT) **Note: The reported position value of ~$5.9B on 148,314 shares appears to be a data error — VTVT's entire market cap is a fraction of that figure. The share count (~148K) is likely accurate, representing a modest but notable new stake.** Baker Bros. initiating any position in a micro-cap like VTVT is significant given their concentrated, high-conviction style and deep biotech diligence capabilities. VTVT's lead asset is **azeliragon (TTP488)**, an oral GLP-1 receptor agonist being developed for type 2 diabetes, alongside earlier-stage programs including **HPP737** (oral GLP-1) — a therapeutic space attracting enormous capital flows given Novo Nordisk/Lilly